Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $118M | $166M | $223M | $251M | $252M | $242M |
| Revenue growth | — | 40.4% | 34.0% | 12.9% | 0.3% | -4.2% |
| Gross profit | $87.8M | $125M | $180M | $204M | $197M | $183M |
| Gross margin | 74.2% | 75.5% | 80.9% | 81.1% | 78.3% | 75.9% |
| Operating income | -$14.4M | -$27.3M | -$44.0M | -$330M | -$711M | -$224M |
| Operating margin | -12.2% | -16.4% | -19.8% | -131.2% | -281.8% | -92.9% |
| Net income | $0.00 | -$17.8M | -$7.22M | -$202M | -$413M | -$139M |
| Net margin | 0.0% | -10.7% | -3.2% | -80.5% | -163.8% | -57.5% |
| EPS (diluted) | — | -$0.19 | -$0.07 | -$1.79 | -$3.54 | -$1.30 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $23.2M | $25.2M | $35.6M | $41.2M | $58.2M | $53.8M |
| Capital expenditures | $1.40M | $6.73M | $8.33M | $2.98M | $12.3M | $16.7M |
| Free cash flow | $21.8M | $18.5M | $27.3M | $38.2M | $45.9M | $37.1M |
| Share buybacks | — | — | $0.00 | $0.00 | $22.4M | $49.5M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.8M | $387M | $147M | $131M | $105M | $164M |
| Total assets | $1.75B | $2.12B | $2.12B | $1.83B | $1.09B | $735M |
| Total liabilities | $550M | $613M | $641M | $627M | $482M | $357M |
| Long-term debt | $457M | $264M | $256M | $243M | $229M | $156M |
| Shareholders' equity | $1.20B | $1.50B | $1.48B | $1.20B | $607M | $379M |
| Retained earnings | — | -$17.7M | -$25.1M | -$227M | -$641M | -$780M |
| Shares (wtd avg diluted) | — | 91.9M | 101M | 113M | 117M | 107M |
Every figure is extracted from Definitive Healthcare Corp.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.